CD44 and cancer: The development of fluorescence-activated cell sorting (FACS), together with the establishment of specific cell surface markers, permitted the subsequent identification of CSCs in solid tumours [7]: breast (CD44+CD24-/low) [5], prostate and ovarian (CD44+) [19,20], brain and lung (CD133+) cancers [21,22], and others [23-25].